Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Oral Industry Group Holdings Limited
中國口腔產業集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8406)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE IN RELATION TO THE STRATEGIC DEPLOYMENT OF MEDICAL DIGITAL AI COMPUTILITY

The board (the "**Board**") of directors (the "**Directors**") of China Oral Industry Group Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby provides an update to the shareholders (the "**Shareholders**") and potential investors of the Company regarding the latest strategic developments of the Group.

To keep pace with the global development trends in digital medical technology and to promote the long-term growth of the Group, the Group is actively advancing the deep application of artificial intelligence (AI) computing resources in its core medical and dental businesses, as well as developing related digital infrastructure. The Group aims to be an industry partner and strategic investor in the construction of medical AI computing networks and data infrastructure, supporting various scenarios including medical diagnostic imaging, clinical decision support, and intelligent medical services.

The key scopes related to AI medical applications are as follows:

- Establishing a large-scale medical AI computility network, which can significantly enhance the automated intelligent analysis capabilities in areas such as medical imaging (e.g., X-ray imaging (X-ray), computed tomography (CT) scan, magnetic resonance imaging (MRI)), pathological diagnosis, and genetic analysis, so as to assist doctors in making faster and more accurate clinical decisions.

- Creating a platform of medical data security circulation and management to promote compliant sharing of medical data resources, effectively facilitating innovative applications such as new drug development, disease prediction, and telemedicine.

- Introducing internationally advanced medical AI technologies and resources from interdisciplinary professional institutions to strengthen the Group's medical services and technological empowerment advantages, and to enhance service quality and operational efficiency.

This strategic deployment is of great importance for the Group. It will leverage its existing foundation of the medical and dental industries, introducing and deepening the application of AI computility resources. This is expected to significantly enhance service quality and operational efficiency, allowing the Group to stay aligned with the development trends of the digital medical industry and proactively seizing market opportunities brought by technological advancement. By continually strengthening technological capabilities and digital infrastructure constructions, the Group anticipates expanding its service scopes, attracting more quality medical institutions and strategic partners, further consolidating its industry position, and potentially exploring new growth points. Ultimately, this will drive the sustainable development of the Group and create long-term and stable value returns for Shareholders.

The Group hereby emphasizes that the above business plan and strategic deployment are still in their preliminary stage, and the scopes of AI medical applications applicable to the Group will depend on the actual situation of the Group in the future. As at the date of this announcement, the Group has not entered into any legally binding agreements regarding any specific collaborations. Further announcement(s) regarding any significant developments will be made by the Group in accordance with the applicable requirements of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited as and when appropriate.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By Order of the Board
China Oral Industry Group Holdings Limited
Yan Ping
Chairlady and executive Director

Hong Kong, 30 July 2025

As at the date of this announcement, the Board comprises Ms. Yan Ping, Mr. Liu Yao Guang and Mr. Xiao Jiansheng as executive Directors; and Ms. Deng Xin, Ms. Lian Jingyu and Ms. Tseung Choi Wing Queenie as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk on the "Latest Listed Company Information" page for at least 7 days from the date of its posting and on the Company's website at www.chinaoral.co.